More promisingly, Ge et al. [36] showed that the use of a PD-L1 blocking antibody during ex vivo priming of antigen-specific T cells and subsequent DC vaccination resulted in a better cytokine production and expansion of these T cells in vitro, and an improved anti-tumor effect in vivo. Here, CD274 is linked to neoplasm.